Alterity Therapeutics
- Company typePublic
- Founded1997
- HeadquartersParkville, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Alterity Therapeutics firmographics
Firmographics- Name
- Alterity Therapeutics
- Legal name
- Alterity Therapeutics
- Website
- https://alteritytherapeutics.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Alterity Therapeutics industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals (neurodegenerative disease therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Alterity Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Parkville
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Alterity Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- ATH434 Commercialization (Projected): Pre-commercial biotechnology company with no current revenue. Projected peak worldwide sales of ATH434 exceeding $1.2 billion by fiscal year 2035, with risk-adjusted sales exceeding $500 million upon successful Phase 3 completion and FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Alterity Therapeutics product offering
Product offeringCore offering
Alterity Therapeutics is a clinical-stage biotechnology company developing ATH434, a first-in-class investigational drug candidate for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The compound works by reducing iron accumulation and inhibiting protein aggregation in the brain, with Phase 2 trials showing approximately 41-48% slowing of disease progression at the 50mg BID dose.
Product overview
Alterity Therapeutics is a clinical-stage biotechnology company developing first-in-class drug candidates for neurodegenerative diseases. The company's lead asset is ATH434, a drug candidate in late-stage clinical development for Multiple System Atrophy (MSA). ATH434 is supported by the bioMUSE Natural History Study, a biomarker research program conducted with Vanderbilt University Medical Center. The company is preparing to initiate Phase 3 pivotal trials for ATH434 following positive FDA feedback.
Differentiator
Problem solved
Functional benefit
Products and services
- ATH434 ATH434 is a first-in-class investigational drug candidate in Phase 2/3 clinical development for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. It reduces brain iron accumulation and inhibits protein aggregation, demonstrating approximately 41-48% slowing of disease progression at the 50mg BID dose, with positive effects on swallowing impairment and orthostatic hypotension. It has received FDA Fast Track Designation and Orphan Drug Designation from both FDA and the European Commission.
Quantifiable outcome
- 41% relative treatment effect on MuSyCA scale at Week 52 (p=0.034)
- +3 more outcomes
Companies that use Alterity Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Alterity Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alterity Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Vanderbilt University Medical CentercoreCollaboration on the bioMUSE Natural History Study, a critical research initiative that generated data for developing QSM MRI as a biomarker for Multiple System Atrophy. The partnership enabled peer-reviewed publication in NeuroImage demonstrating iron accumulation detection and disease severity tracking capabilities.
- Insilico MedicineminorAlterity Therapeutics is listed among companies advancing in longevity and neurodegeneration research alongside Insilico Medicine, which created the industry's first AI Longevity Board.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Alterity Therapeutics competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Major pharmaceutical company with extensive CNS and neurology pipeline including Parkinson's programs, comparable as a large-cap incumbent with both competitive and partnership overlap.
- Takeda Pharmaceutical: Global pharmaceutical company with significant CNS and rare disease franchises and a track record of partnering with and acquiring late-stage biotech assets, highly relevant as a potential strategic acquirer of ATH434.
- Lundbeck: Established CNS specialty pharmaceutical company with Parkinson's disease franchises (e.g., Onapgo), offering a strategic partnership and comparator profile for late-stage rare neurology assets.
Emerging players
- Clene Nanomedicine: Clinical-stage biotech developing nanocatalytic therapeutics for neurodegenerative diseases including Parkinson's and ALS, sharing a similar mechanism-of-action-driven approach to orphan neurology indications.
- Ionis Pharmaceuticals: Antisense oligonucleotide platform company with multiple CNS/rare neurology programs, comparable as a clinical-stage developer of novel modality therapies for neurodegenerative and rare neurological indications.
- Voyager Therapeutics: Gene therapy company focused on CNS/neurodegenerative diseases including Parkinson's, comparable as a late-stage clinical biotech operating in the same therapeutic space with disease-modifying ambitions.
Direct peers
- Mitsubishi Tanabe Pharma: Japanese pharma company with active MSA and neurodegenerative disease research programs, including radicut/edaravone work, directly comparable in rare neurology pipeline focus.
- Prilenia Therapeutics: Clinical-stage biotech developing pridopidine for MSA and Huntington's disease, directly competing with Alterity in the rare neurodegenerative disorder space with a similar orphan-drug and disease-modifying strategy.
- Sage Therapeutics: Neurology/CNS specialty pharmaceutical company developing CNS-targeted therapeutics for rare neurological disorders, sharing a similar orphan-drug, late-stage development, and regulatory designation playbook with Alterity.
- Biohaven Pharmaceutical (Pfizer): Acquired by Pfizer, Biohaven was a CNS-focused biotech with neurodegenerative and rare neurology programs, providing a comparable development and commercialization template for rare CNS disease assets.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Alterity Therapeutics social profiles
Digital presenceAlterity Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alterity Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Alterity Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alterity Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alterity Therapeutics
What does Alterity Therapeutics do?
Alterity Therapeutics is a clinical-stage biotechnology company developing ATH434, a first-in-class investigational drug candidate for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The compound works by reducing iron accumulation and inhibiting protein aggregation in the brain, with Phase 2 trials showing approximately 41-48% slowing of disease progression at the 50mg BID dose.
Is Alterity Therapeutics a public or private company?
Alterity Therapeutics is a public company. It is classified as public and is currently operating.
When was Alterity Therapeutics founded?
Alterity Therapeutics was founded in 1997. It employs 1 to 10 people.
Where is Alterity Therapeutics based?
Alterity Therapeutics is headquartered in Parkville, Australia, in the Oceania region.
How does Alterity Therapeutics make money?
One revenue line is on record: ATH434 Commercialization (Projected).
Who are Alterity Therapeutics's main competitors?
Broad incumbents on record are AbbVie, Takeda Pharmaceutical and Lundbeck. Emerging players are Clene Nanomedicine, Ionis Pharmaceuticals and Voyager Therapeutics. Direct peers are Mitsubishi Tanabe Pharma, Prilenia Therapeutics, Sage Therapeutics and Biohaven Pharmaceutical (Pfizer).
Does Alterity Therapeutics have an API?
No public API is recorded for Alterity Therapeutics.
What industry is Alterity Therapeutics in?
Alterity Therapeutics's product category is Clinical-stage biopharmaceuticals (neurodegenerative disease therapeutics). Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.